This study sought to understand the evolving continuing medical education (CME) needs of physicians managing patients with tardive dyskinesia (TD). A case-based survey was developed, and later updated, to assess current practice, knowledge, and attitudes of neurologists and psychiatrists in the management of patients with TD. The original and updated survey were fielded in May 2018 and March 2020, respectively, to US-practicing psychiatrists and neurologists. Results were obtained from 213 psychiatrists and 187 neurologists in 2018 and from 125 psychiatrists and 128 neurologists in 2020. Less than half of physicians in both 2018 and 2020 were able to correctly identify the prevalence of TD in patients on maintenance antipsychotics, with many underestimating reported prevalence. Respondents reported moderate familiarity with VMAT2 inhibitor therapies for TD, with self-reported familiarity increasing more among neurologists than psychiatrists since the 2018 study. Psychiatrists are more likely than neurologists to take responsibility for medical management of TD symptoms and antipsychotic medication adjustment. Despite recommendations from APA guidelines and AAN reviews, 15% of physicians would use an anticholinergic to manage TD symptoms and only about half would opt for a VMAT2 inhibitor. There was a larger increase in VMAT inhibitor use between 2018 and 2020 among neurologists as compared to psychiatrists. The findings support the need for CME on TD focused toward specific provider groups. While both types of specialists would benefit from CME on the topic of TD epidemiology, there is an increased need for CME that includes treatment updates among psychiatrists.Funding. Neurocrine Biosciences, Inc.

中文翻译：

---

了解医生管理 TD 患者不断变化的继续医学教育需求

本研究旨在了解管理迟发性运动障碍 (TD) 患者的医生不断发展的继续医学教育 (CME) 需求。开发并随后更新了一项基于病例的调查，以评估神经科医生和精神科医生在治疗 TD 患者方面的当前实践、知识和态度。最初和更新的调查分别于 2018 年 5 月和 2020 年 3 月向美国执业的精神科医生和神经科医生进行了调查。结果来自 2018 年的 213 名精神科医生和 187 名神经科医生，以及 2020 年的 125 名精神科医生和 128 名神经科医生。在 2018 年和 2020 年，只有不到一半的医生能够正确识别维持性抗精神病药物患者的 TD 患病率，其中许多被低估了流行。受访者报告对 TD 的 VMAT2 抑制剂疗法的熟悉程度中等，自 2018 年研究以来，神经科医生的自我报告熟悉程度高于精神科医生。精神科医生比神经科医生更有可能负责 TD 症状的医疗管理和抗精神病药物调整。尽管 APA 指南和 AAN 审查提出了建议，但 15% 的医生会使用抗胆碱能药物来控制 TD 症状，而只有大约一半的医生会选择 VMAT2 抑制剂。与精神科医生相比，神经科医生在 2018 年至 2020 年间使用 VMAT 抑制剂的人数增加较多。研究结果支持针对特定提供者群体的 TD 的 CME 的必要性。虽然这两种类型的专家都将从 CME 中受益于 TD 流行病学主题，资金。神经内分泌生物科学公司